Home »

ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference

YONKERS, NY — (Marketwired) — 12/04/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company–s chief executive officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10, 2014 at 4:30 PM ET. Ms. Greg

ContraFect Submits Complete Response to IND Clinical Hold for CF-301

YONKERS, NY — (Marketwired) — 12/02/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA). The complete response addresses all of the issues identified in the Investigational New Drug Application (IND) clinical hold letter

ContraFect Corporation Announces Third Quarter 2014 Results

YONKERS, NY — (Marketwired) — 11/14/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014. For the three month period ended September 30, 2014, the Company posted a net loss of $16.4 m

ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment

YONKERS, NY — (Marketwired) — 10/09/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that they have entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC ("IVDC") to advance research and development of CF-404, its Universa

ContraFect Corporation to Present at the 13th Annual BIO Investor Forum

YONKERS, NY — (Marketwired) — 09/30/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug resistant infectious diseases, announced today that Julia P. Gregory, the Company–s chief executive officer and Barry Kappel, the Company–s senior vice president of business development, will present a corporate overview at the 13th Annual BIO Investor Forum at The

ContraFect Corporation Expands Senior Management Team

Hires Natalie Bogdanos as General Counsel

ContraFect Corporation to Present at BioCentury–s 21st Annual NewsMakers in the Biotech Industry Conference

YONKERS, NEW YORK — (Marketwired) — 09/19/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company–s chief executive officer and Barry Kappel, the Company–s senior vice president of business development, will present a corporate overview at BioCentury–s 21st Annual NewsMakers in the Biotech Industry Conference at the Millenni

ContraFect Corporation–s Universal Influenza Treatment Receives SBIR Funding

YONKERS, NY — (Marketwired) — 09/16/14 — (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NI

Analytics

© 2021 88Finance. All Rights Reserved. Log in

- Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de